Celcuity Inc. Schedules Release of Third Quarter 2020 Financial Results and Conference Call
Celcuity Inc. (Nasdaq: CELC) has announced the release of its financial results for the third quarter of 2020 on November 9, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celcuity Inc. (Nasdaq: CELC) has announced the release of its financial results for the third quarter of 2020 on November 9, 2020, after market close. A teleconference will follow at 4:30 p.m. ET to discuss these results. The company specializes in innovative cancer diagnostics through its CELsignia platform, which analyzes living tumor cells to identify new cancer sub-types that traditional diagnostics may miss. This advancement aims to improve patient outcomes and enhance targeted therapy definitions.
Positive
- Anticipated financial results of Q3 2020 may show growth potential.
- Innovative CELsignia platform could enhance diagnostic capabilities in cancer treatment.
Negative
- None.
Details
News Market Reaction – CELC
The recorded move for CELC in the trading session of this news was -0.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, MN / ACCESSWIRE / October 26, 2020 / Celcuity Inc. (Nasdaq:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the third quarter 2020 after the stock market close on Monday, November 9, 2020. Management will host a teleconference the same day at 4:30 p.m. Eastern Time (ET) to discuss the results.
Conference Call Details
Participants should dial 1-866-831-8616 and use passcode 33954. Participants are asked to dial in 5 to 10 minutes prior to the start of the call.
About Celcuity
Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's proprietary CELsignia diagnostic platform analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. We are driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com
Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including the anticipated benefits to the clinical outcomes of cancer patients. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, those set forth in the Risk Factors section of Celcuity's Annual Report on Form 10-K for the year ended December 31, 2019. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
SOURCE: Celcuity Inc.
View source version on accesswire.com:
https://www.accesswire.com/612304/Celcuity-Inc-Schedules-Release-of-Third-Quarter-2020-Financial-Results-and-Conference-Call
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.